Efficacy of the Neurokinin-1 Receptor Antagonist Rolapitant in Preventing Nausea and Vomiting in Patients Receiving Carboplatin-Based Chemotherapy

Cancer

Volumn 122, Issue 15, 2016, Pages 2418-2425

  Hesketh, Paul J ^a   Schnadig, Ian D ^b   Schwartzberg, Lee S ^c   Modiano, Manuel R ^d   Jordan, Karin ^e   Arora, Sujata ^f   Powers, Dan ^f   Aapro, Matti ^g  

^a LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^b US Oncology Research ^*  (United States)

^c West Clinic   (United States)

^d Arizona Oncology Associates   (United States)

^e MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^f TESARO   (United States)

^g CLINIQUE DE GENOLIER   (Switzerland)

Author keywords

Carboplatin; Chemotherapy induced nausea and vomiting; Moderately emetogenic chemotherapy; Neurokinin 1 receptor antagonist; Rolapitant

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; GRANISETRON; IDARUBICIN; IFOSFAMIDE; IRINOTECAN; ROLAPITANT; 8-((1-(3,5-BIS(TRIFLUOROMETHYL)PHENYL)ETHOXY)METHYL)-8-PHENYL-1,7-DIAZASPIRO(4,5)DECAN-2-ONE; ANTINEOPLASTIC AGENT; NEUROKININ 1 RECEPTOR ANTAGONIST; SPIRO COMPOUND;

ADULT; AGED; ANEMIA; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEAD AND NECK CANCER; HUMAN; INCIDENCE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; OVARY CANCER; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; UTERUS CANCER; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COMPLICATION; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NAUSEA; NEOPLASMS; PHASE 3 CLINICAL TRIAL; RISK FACTOR; TREATMENT OUTCOME; VERY ELDERLY; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHEMOPREVENTION; FEMALE; HUMANS; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; NEUROKININ-1 RECEPTOR ANTAGONISTS; RISK FACTORS; SPIRO COMPOUNDS; TREATMENT OUTCOME; VOMITING;

EID: 84970027604     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.30054     Document Type: Article

References (23)

1. Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med. 2008; 358: 2482–2494.
2. Jordan K, Janh F, Aapro M. Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review. Ann Oncol. 2015;26:1081–1090.
3. Roila F, Donati D, Tamberi S, Marquitti G. Delayed emesis: incidence, pattern, prognostic factors and optimal treatment. Support Care Cancer. 2002;10:88–95.
4. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Antiemesis. Version 2. 2015. http://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf. Accessed October 10, 2015.
5. Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2011;29:4189–4198.
6. Roila F, Herrstedt J, Appro M, et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapyinduced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol. 2010;21(suppl 5):v232–v243.
7. Martin M, Diaz-Rubio E, Sanchez A, Almenarez J, Lopez-Vega JM. The natural course of emesis after carboplatin treatment. Acta Oncol. 1990;29:593–595.
8. du Bois A, Vach W, Cramer-Giraud U, Thomssen C, Glaubitz M, Fiola M. Pattern of carboplatin-induced emesis. Anticancer Drugs. 1995;6:645–651.
9. Waqar MA, Chitneni P, Williams K, et al. A prospective study on the incidence of delayed nausea and vomiting following administration of carboplatin containing regimens for treatment of cancer without prophylactic aprepitant. J Clin Oncol. 2008;26(suppl):20626. VARUBI [package insert]. Waltham, MA: TESARO Inc; 2015.
10. Poma A, Christensen J, Pertikis H, et al. Rolapitant and its major metabolite do not affect the pharmacokinetics of midazolam, a sensitive cytochrome P450 3A4 substrate [abstract 441]. Support Care Cancer. 2013;21:S154.
11. Schwartzberg L, Modiano M, Rapoport B, et al. Safety and efficacy assessment of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial. Lancet Oncol. 2015;16:1071–1078.
12. Rapoport B, Chasen, M, Gridelli C, et al. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials. Lancet Oncol. 2015;16:1079–1089.
13. Lindley CM, Hirsch JD, O’Neill CV, Transau MC, Gilbert CS, Osterhaus JT. Quality of life consequences of chemotherapy induced emesis. Qual Life Res. 1992;1:331–340.
14. Martin AR, Pearson JD, Cai B, Elmer M, Horgan K, Lindley C. Assessing the impact of chemotherapy-induced nausea and vomiting on patients’ daily lives: a modified version of the Functional Living Index–Emesis (FLIE) with 5-day recall. Support Care Cancer. 2003; 11:522–527.
15. Gralla R, Jordan K, Rapoport B, et al. Assessing the magnitude of antiemetic benefit with the addition of the NK1 receptor antagonist (NK1) aprepitant for all platinum agents: analysis of 1,872 patients (pts) in prospective randomized clinical phase III trials (RCTs) [abstract 9057]. J Clin Oncol. 2010;28(suppl):15S.
16. Jordan K, Gralla RJ, Rizzi G. Should all antiemetic guidelines recommend an NK1-containing regimen in patients receiving carboplatin: efficacy evaluation of NEPA, a fixed combination of the NK1 receptor antagonist, netupitant, and palonosetron. Poster presented at: American Society of Clinical Oncology 2015 Annual Meeting; May 29-June 2, 2015; Chicago, IL.
17. Weinstein C, Jordan K, Green SA, et al. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial. Ann Oncol. 2016;27:172–178.
18. Rapoport BL, Jordan K, Boice JA, et al. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer. 2010; 18:423–431.
19. Yahata H, Sonoda K, Kobayashi H, et al. A prepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy: a multicenter, placebo-controlled, double-blind, randomized study of Japanese gynecologic cancer patients receiving paclitaxel and carboplatin. Ann Oncol. 2014; 25: 4517–4541.
20. Ito Y, Karayama M, Inui N, et al. Aprepitant in patients with advanced non–small-cell lung cancer receiving carboplatin-based chemotherapy. Lung Cancer. 2014;84:259–264.
21. Tanioka M, Kitao A, Matsumoto K, et al. A randomised, placebocontrolled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy. Br J Cancer. 2013;109:859–865.
22. Kusagaya H, Inui N, Karayama M, et al. Evaluation of palonosetron and dexamethasone with or without aprepitant to prevent carboplatin-induced nausea and vomiting in patients with advanced non–small-cell lung cancer. Lung Cancer. 2015;90:410–416.
23. Jordan K, Gralla R, Rossi G, Borroni ME, Rizzi G. Is the addition of an NK1 receptor antagonist beneficial in patients receiving carboplatin? Supplementary data with NEPA, a fixed dose combination of netupitant and palonosetron. Paper presented at: Annual Meeting of the Multinational Association of Supportive Care in Cancer; June 26–28, 2014; Miami, FL.